2025-524982-25-00Not yet recruitingPhase 4
Antibiotic Prophylaxis in Hematopoietic Stem Cell Transplantation: a Randomised Controlled Trial - The ANTURA trial
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Sept 2026
Brief summary (registry, in English)
The primary objective of this study is to evaluate whether antibacterial prophylaxis with levofloxacin reduces the incidence of bloodstream infections during the neutropenic phase (up to 30 days) following allogeneic hematopoietic stem cell transplantation compared with placebo.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 23 Jul 2026
- Start date
- 5 Oct 2026
- Lead sponsor
- HUS-yhtymae
- Diseases
- Myelodysplastic syndromes
- EU CT number
- 2025-524982-25-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 150
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known hypersensitivity to fluoroquinolone antibiotics
- Epilepsy or other known seizure disorder
- History of tendinopathy during fluoroquinolone therapy
Lab values
- Long-QT syndrome
- Acquired prolonged QT-time, cQT>500ms
Other
- Pregnancy of breastfeeding
- Other known contraindication to levofloxacin or other fluoroquinolone antibiotics
Who the study is looking for
- Adults (≥18 years) scheduled to undergo allogeneic hematopoietic stem cell transplantation at Helsinki University Hospital for any accepted indication.
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| HUS-Yhtymae | Helsinki | Finland | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.